Takeda-Ascentage Pharma to Be Eligible for Option Exercise Fee, Additional Potential Milestone IF Co Exercises Option to License Olverembatinib
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.